Houston, TXNCT03596086Now EnrollingIRB Ready

Glioblastoma Multiforme Clinical Trial in Houston, TX

Access cutting-edge glioblastoma multiforme treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by David Baskin MD

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access glioblastoma multiforme specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related glioblastoma multiforme treatment provided free

Apply for This Houston Location

Check if you qualify for this glioblastoma multiforme clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This Glioblastoma Multiforme Study in Houston

Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.

Sponsor: David Baskin MD

Who Can Participate

Inclusion Criteria

All patients must have biopsy proven recurrent anaplastic astrocytoma or glioblastoma multiforme without evidence of multifocal tumor or brainstem involvement. Multifocal disease does not exist if enhancing areas are connected by abnormal T2 FLAIR on the MRI scan.
Radiographic evidence of recurrence/progression by iRANO criteria
≥ 3 weeks since any major surgery, completion of RT, or completion of all prior systemic anticancer therapy (adequately recovered from the acute toxicities of any prior therapy).
Life expectancy ≥ 12 weeks.
Patient can receive second treatment of HSV-tk after 6 months
Patients should have the following characteristics: recurrent glioblastoma or AA demonstrated by biopsy or imaging study, ECOG performance status of 0-1, has had prior surgery and radiotherapy /chemotherapy for the glioblastoma.
Patients with leptomeningeal disease may be considered for enrollment into the study.
No evidence of other active malignancy (except squamous or basal cell skin cancers).
Signed informed consent to participate in the study must be obtained from patients after they have been fully informed of the nature and potential risks of the study by the investigator (or his/her designee) with the aid of written information.
Willing to provide biopsies as required by the study.
WOCBP must have a negative serum pregnancy test within 7 days prior to the administration of the first study treatment. Women must not be lactating.
WOCBP and men must practice an effective method of birth control
Patients must have adequate baseline organ function as assessed by the following laboratory values before initiating the protocol:
serum creatinine \< 1.5 mg/dL
T. bilirubin \< 2.5 mg/dL, ALT, AST, GGT and AP \< 2 x normal
Platelet count. \> 100,000/ml , ANC\> 1500/ml , Hgb\> 10 gm/dL
Normal partial thromboplastin time (PTT) and Pro-Thrombin Time (PT)
Non English speaking patients can participate in this study

Exclusion Criteria

Prior treatment with immunomodulatory therapy, immunotherapy, and/or gene vector therapy in the past 3 months.
Any cytotoxic chemotherapy, RT, or immunotherapy or any investigational drug for this brain tumor within 3 weeks of study treatment start.
Evidence of multifocal disease, brainstem involvement
Patients on immunosuppressive drugs (other than steroids for brain edema).
In patients with leptomeningeal disease, no evidence of diffuse disease or spread to the spine.
In patients with leptomeningeal disease, no bulky leptomeningeal metastases with potential to obstruct CSF flow will not be enrolled.
Liver disease, such as cirrhosis or active/chronic hepatitis B or C.
History of or current alcohol misuse/abuse within the past 12 months.
Known or suspected allergy or hypersensitivity to any component of the proposed regimen (gene vector-HSV-tk, Valacyclovir).
Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications (Valacyclovir).
No active malignancy except for non-melanoma skin cancer or in situ cervical cancer or treated cancer from which the patient has been continuously disease free for more than 5 years.
Pregnant or breastfeeding women or women/men able to conceive and unwilling to practice an effective method of birth control. WOCBP must have a negative serum pregnancy test within 7 days prior to the administration of the first study treatment.
Presence of active or suspected acute or chronic uncontrolled infection or history of immunocompromise, including a positive HIV test result.
Patients \< 18 years of age
Unwilling or unable to comply with the study protocol.
The presence of active CNS toxoplasmosis infection or Progressive Multifocal Leukoencephalopathy demonstrated on CT or MRI imaging.
The presence of active untreated cellulitis or untreated wound infections. Treated and resolving cellulitis and infections are not an exclusion criteria.
Active IV drug abuse or severe opioid abuse

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT03596086) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Glioblastoma Multiforme Treatment Options in Houston, TX

If you're searching for glioblastoma multiforme treatment options in Houston, TX, this clinical trial (NCT03596086) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma multiforme specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all glioblastoma multiforme clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Houston, TX

See all brain cancer clinical trials recruiting in Houston — not just this study.

Browse Brain Cancer Trials in Houston →

Browse More Trials by Condition

Brain Cancer TrialsAnkylosing Spondylitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX